Elucidation of HMA resistance mechanism enables us to rationally identify small molecules that may be more potent and selective than ATRA in killing HMA‐resistant AML cells—through constructing and screening library composed of potential RARα agonists. This evidence concerns the gene RARA and acute myeloid leukemia.